Caribou生物科学开始第一阶段试验,进行新的狼疮治疗(CB-010),并计划扩大到其他癌症。 Caribou Biosciences begins Phase 1 trial for new lupus treatment, CB-010, with plans to expand to other cancers.

Caribou生物科学已开始对CB-010进行第一阶段试验,以治疗乳腺肾炎和外肾膜炎。 Caribou Biosciences has started a Phase 1 trial for CB-010 to treat lupus nephritis and extrarenal lupus. 该公司还计划在2025年年中之前分享淋巴瘤病人的CB-010和多种骨髓瘤病人的CB-011的数据。 The company also plans to share data from CB-010 in lymphoma patients and CB-011 in multiple myeloma patients by mid-2025. Caribou的目标是在今年晚些时候开始对淋巴瘤病人进行关键的第3阶段的CB-010试验,等待林业发展局批准和确认他们的HLA匹配战略。 Caribou aims to begin a pivotal Phase 3 trial for CB-010 in lymphoma patients later this year, pending FDA approval and confirmation of their HLA matching strategy.